For the sixth year running, Pfizer's pharmaceutical sales team has cometop of a Scott-Levin survey of US physicians. 33 physician specialty groups and other health care providers were surveyed for the report, with around 12,000 people in total being questioned.
Pfizer was followed by SmithKline Beecham in second place, while the American Home Product unit, Wyeth-Ayerst, came third. Merck & Co's sales force was fourth favorite in the survey, followed by Glaxo Wellcome and Bristol-Myers Squibb.
Of nine key physician groups questioned, Pfizer was rated top by five of them: general/family practitioners, internists, cardiologists, pediatricians and general surgeons. In addition, the New York-based giant came first in the eyes of urologists, nephrologists, emergency medicine specialists, neurosurgeons, nurse practitioners and physician assistants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze